- Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2021 Virtual Congress
- Antengene's Partner Karyopharm Therapeutics Announces Updated Data of Eltanexor in Patients with Hypomethylating Agent Refractory MDS
- Karyopharm Announces Key Changes to Its Commercial Leadership Team
- Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets
- Karyopharm Receives Conditional Marketing Authorization in the United Kingdom (UK) for NEXPOVIO® (selinexor) in Combination with Dexamethasone for the Treatment of Adult Patients with Relapsed and or Refractory Multiple Myeloma
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Karyopharm to Participate at Jefferies 2021 Virtual Healthcare Conference
- Karyopharm Announces Open Enrollment At Participating Hospitals In Europe For A Phase 3 Maintenance Study Evaluating Selinexor In Patients With Endometrial Cancer After Combination Chemotherapy
- Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting
- Antengene Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer
Karyopharm Therapeutics Inc (KPTI:NSQ) closed at 10.43, 34.06% above the 52 week low of 7.78 set on May 06, 2021.
7.78May 06 202120.99Jun 22 2020
Markit short selling activity
|Market cap||793.73m USD|
|EPS (TTM)||-2.72 |
Data delayed at least 15 minutes, as of Jun 22 2021 21:00 BST.